Single Time Point Whole-Body Tumour Dosimetry as an Independent Prognostic Biomarker for Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Lutetium-177 [177Lu]Lu-PSMA-617

被引：0
|
作者：
Eifer, M. [1 ,2 ,3 ,4 ]
Papa, N. [1 ,2 ]
Kashyap, R. [1 ,2 ,5 ]
Buteau, J. P. [1 ,2 ,5 ]
McIntosh, L. [1 ,2 ]
Alipour, R. [1 ,2 ,5 ]
Azad, A. A. [5 ,6 ]
Akhurst, T. [1 ,2 ]
Cardin, A. [1 ,2 ,5 ]
Chen, D. [1 ,2 ]
Emmerson, B. [1 ,2 ]
Fettke, H. [5 ,7 ]
Haskali, M. [1 ,2 ,5 ]
Jewell, K. [1 ,2 ,5 ]
Kong, G. [1 ,2 ,5 ]
Kostos, L. [5 ,6 ]
Kumar, A. S. Ravi [1 ,2 ,5 ]
Macfarlane, L. [1 ,2 ]
Medhurst, E. [1 ,2 ,5 ]
Murphy, D. G. [5 ,8 ]
Saghebi, J. [1 ,2 ,5 ]
Sandhu, S. [5 ,6 ]
Tran, B. [5 ,6 ]
Jackson, P. [1 ,2 ,5 ]
Hofman, M. S. [1 ,2 ,5 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Imaging, Mol Imaging & Therapeut Nucl Med, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Vic, Australia
[3] Chaim Sheba Med Ctr, Dept Diagnost Imaging, Ramat Gan, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[7] Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia
[8] Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-578
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 50 条
  • [41] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
    Hojjat Ahmadzadehfar
    Simone Wegen
    Anna Yordanova
    Rolf Fimmers
    Stefan Kürpig
    Elisabeth Eppard
    Xiao Wei
    Carl Schlenkhoff
    Stefan Hauser
    Markus Essler
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1448 - 1454
  • [42] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
    Ahmadzadehfar, Hojjat
    Wegen, Simone
    Yordanova, Anna
    Fimmers, Rolf
    Kuerpig, Stefan
    Eppard, Elisabeth
    Wei, Xiao
    Schlenkhoff, Carl
    Hauser, Stefan
    Essler, Markus
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) : 1448 - 1454
  • [43] 177Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival
    Demirci, E.
    Akyel, R.
    Sahin, O.
    Ocak, M.
    Aygun, A.
    Pehlivanoglu, H.
    Karayel, E.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S203
  • [44] Re-challenge [177Lu]Lu-PSMA-617 in patients with advanced prostate cancer: outcome and safety
    Yordanova, Anna
    Essler, Markus
    Hauser, Stefan
    Feldmann, Georg
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [45] LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Kostos, Louise Kathleen
    Buteau, James Patrick
    Kong, Grace
    Yeung, Theresa
    Di Iulio, Juliana
    Fahey, Michael T.
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [46] Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.
    Herrmann, Ken
    Gafita, Andrei
    De Bono, Johann S.
    Sartor, A. Oliver
    Chi, Kim N.
    Krause, Bernd J.
    Rahbar, Kambiz
    Tagawa, Scott T.
    Czernin, Johannes
    El-Haddad, Ghassan
    Wong, Connie
    Zhang, Zhaojie
    Wilke, Celine
    Mirante, Osvaldo
    Morris, Michael J.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 208 - 208
  • [47] [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
    Hofman, Michael S.
    Emmett, Louise
    Sandhu, Shahneen
    Iravani, Amir
    Joshua, Anthony M.
    Goh, Jeffrey C.
    Pattison, David A.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Ng, Siobhan
    Francis, Roslyn J.
    Gedye, Craig
    Rutherford, Natalie K.
    Weickhardt, Andrew
    Scott, Andrew M.
    Lee, Sze-Ting
    Kwan, Edmond M.
    Azad, Arun A.
    Ramdave, Shakher
    Redfern, Andrew D.
    Macdonald, William
    Guminski, Alex
    Hsiao, Edward
    Chua, Wei
    Lin, Peter
    Zhang, Alison Y.
    McJannett, Margaret M.
    Stockler, Martin R.
    Violet, John A.
    Williams, Scott G.
    Martin, Andrew J.
    Davis, Ian D.
    LANCET, 2021, 397 (10276): : 797 - 804
  • [48] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [49] Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer
    Yadav, Madhav P.
    Ballal, Sanjana
    Tripathi, Madhavi
    Damle, Nishikant A.
    Sahoo, Ranjit K.
    Seth, Amlesh
    Bal, Chandrasekhar
    NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (01) : 91 - 98
  • [50] Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu] Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
    Fettke, Heidi
    Kostos, Louise
    Buteau, James
    Steen, Jason A.
    Medhurst, Elizabeth
    Haskali, Mo B.
    Murphy, Declan
    Docanto, Maria
    Bukczynska, Patricia
    Ng, Nicole
    Sandhu, Shahneen
    Foroughi, Siavash
    Furic, Luc
    Nguyen-Dumont, Tu
    Hofman, Michael S.
    Azad, Arun A.
    CANCER RESEARCH, 2023, 83 (07)
12345